Market research
ZNTL Zentalis Pharmaceuticals Llc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 367M
- P/E ratio
- Not available
- Analyst target
- 6.8889
- Dividend yield
- Not available
- Beta
- 1.89
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98943L1070
- Market cap
- 367M
- P/E ratio
- Not available
- Analyst target
- 6.8889
- Dividend yield
- Not available
- Beta
- 1.89
About
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ZNTL discussion.
5 years, 4 months ago
Zentalis Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 6.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Zentalis Pharmaceuticals, Inc gets an overall score of 2/5.